Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity.
about
A form of the metabolic syndrome associated with mutations in DYRK1BTwo-way communication between the metabolic and cell cycle machineries: the molecular basisPossible involvement of Opa-interacting protein 5 in adipose proliferation and obesityMetabolic syndrome: genetic insights into disease pathogenesisDevelopment of an OP9 derived cell line as a robust model to rapidly study adipocyte differentiation.Adipocyte progenitor cells initiate monocyte chemoattractant protein-1-mediated macrophage accumulation in visceral adipose tissue.Large-scale in silico mapping of complex quantitative traits in inbred mice.Multiple roles for the non-coding RNA SRA in regulation of adipogenesis and insulin sensitivity.Gene expression profiling of subcutaneous adipose tissue in morbid obesity using a focused microarray: distinct expression of cell-cycle- and differentiation-related genesCyclin D3 promotes adipogenesis through activation of peroxisome proliferator-activated receptor gamma.Methylglyoxal mediates adipocyte proliferation by increasing phosphorylation of Akt1Integrative analysis of a cross-loci regulation network identifies App as a gene regulating insulin secretion from pancreatic islets.Cycling through metabolism.Genome-wide expression in visceral adipose tissue from obese prepubertal childrenCyclin-dependent kinase inhibitor, p21WAF1/CIP1, is involved in adipocyte differentiation and hypertrophy, linking to obesity, and insulin resistance.New targets to treat obesity and the metabolic syndrome.Impact of Obesity and Metabolic Syndrome on Immunity.Primary cilia in energy balance signaling and metabolic disorder.Enhanced beta cell proliferation in mice overexpressing a constitutively active form of Akt and one allele of p21Cip.Helenalin-mediated post-transcriptional regulation of p21(Cip1) inhibits 3T3-L1 preadipocyte proliferationIdentification of a loss-of-function mutation in Ube2l6 associated with obesity resistance.Phosphorylation at tyrosine 114 of Proliferating Cell Nuclear Antigen (PCNA) is required for adipogenesis in response to high fat dietMetabolic regulation of the cell cycle.MicroRNA-27 (miR-27) targets prohibitin and impairs adipocyte differentiation and mitochondrial function in human adipose-derived stem cells.HO-1 inhibits preadipocyte proliferation and differentiation at the onset of obesity via ROS dependent activation of Akt2.Response of the adipose tissue transcriptome to dihydrotestosterone in mice.Curcumin Inhibits 3T3-L1 Preadipocyte Proliferation by Mechanisms Involving Post-transcriptional p27 Regulation.Cell-cycle arrest in mature adipocytes impairs BAT development but not WAT browning, and reduces adaptive thermogenesis in mice.Akt-dependent Skp2 mRNA translation is required for exiting contact inhibition, oncogenesis, and adipogenesis.PPARγ ligand production is tightly linked to clonal expansion during initiation of adipocyte differentiation.An In Vitro Model to Probe the Regulation of Adipocyte Differentiation under Hyperglycemia.SIRT1 Limits Adipocyte Hyperplasia through c-Myc InhibitionMetabolic and histochemical characteristics of fat and muscle tissues in homozygous or heterozygous pigs for the body composition QTL located on chromosome 7.HMGA1 overexpression in adipose tissue impairs adipogenesis and prevents diet-induced obesity and insulin resistance.Re-thinking cell cycle regulators: the cross-talk with metabolism.Inhibitor of Differentiation-3 and Estrogenic Endocrine Disruptors: Implications for Susceptibility to Obesity and Metabolic Disorders.Skp2 controls adipocyte proliferation during the development of obesity.p53 Functions in Adipose Tissue Metabolism and Homeostasis
P2860
Q24297819-6F97E6AC-C117-4017-A82E-A5D3C824106BQ27013594-A53F5C0B-0977-4D2E-954F-A050B7FDFAC4Q27324265-EA554045-8A96-49AF-837C-15DC0064BA7AQ28071007-ECE41508-B12D-4F5F-9B7C-5F803579AC49Q28545038-3BC844B0-A724-4D3F-B400-66AE3063B2EAQ30277975-D5DAC3DF-80CE-4C23-A9E4-38C9FD2A0093Q30502442-DADE9606-757C-48A6-ADCF-CD576A169CF4Q33769840-54E81CAF-6A03-495D-B51E-740CC8810688Q33779549-FC8DE28E-1C7E-4998-9B6A-400FBAD92272Q34124151-0B76B8A0-564C-4522-83C8-9150A0BF1A0BQ34273637-C010F19F-B53A-4629-8D95-8746EB93A8C7Q34510196-D9578CE4-E587-4048-91BF-CA85734AD654Q35054249-57FA259C-8F3A-4042-9416-D8C6A79FB871Q35585547-45E296DC-A177-41EE-AAD2-56E582F06B9CQ35674559-1A507715-474B-44D6-B1CD-8CDBAA670011Q36068914-FC6078F8-C9BF-498C-86D8-0540607A70DCQ36476998-DB42A54D-244F-407A-A986-775DC33535D6Q36685669-25FDDC6C-2701-4D4B-A155-2C744796BBE8Q36823545-4185935A-B3FB-4A8D-B070-BD3042CBEBD1Q36952998-388FA1E4-C375-4DD9-9C97-8CF556E95D15Q37030980-DDCC810F-72DB-410E-A09C-646C5A5353ACQ37047453-933C27AF-067E-4695-890F-AF28D23D164AQ37333099-7E543946-2A11-4077-A81F-ABEC78DE3D43Q37348877-B60AAF5A-2193-47F8-9F77-9D9C52E55CF6Q37593267-28767544-4C6C-427B-9BC9-21251DEF0C6DQ38288014-D0EE57EF-A90E-4FBD-8320-B177002DF8EAQ40187380-D7B1C2E3-6513-46D8-B0D2-2053E4773A03Q41158655-8EF52F31-D4D8-4F31-B397-E4D8262A65DBQ41865466-C95DCD3B-E7DD-4C23-BD77-940E95725494Q41871002-0046B514-6B98-4839-81F9-B1A35DC26C8EQ41881763-81C2D898-A5C5-4237-B98A-DE8FFA0F1730Q41910067-D40E8347-5875-49CD-8710-071E0C1FBE2CQ42510892-65AA65DC-4417-4176-8F22-CAFB1FD33BBDQ42587276-9035F640-3326-4A8A-9B29-E224C9354BB3Q42976643-100BF0ED-8E72-47A1-8DF6-7E93DDB902EFQ51765567-C5631F40-7F46-43B7-82E4-820AC09081F8Q53590143-EBE37465-1C4F-410D-A206-12D13A1AFA5DQ57161298-6A7A5E4B-39CD-45E8-AFFD-7DB075860DBA
P2860
Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity.
@en
Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity.
@nl
type
label
Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity.
@en
Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity.
@nl
prefLabel
Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity.
@en
Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity.
@nl
P2093
P356
P1433
P1476
Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity.
@en
P2093
Amanda Nelson
Denise R Holsberger
Gary A Iwamoto
Hiroaki Kiyokawa
Paul S Cooke
P304
P356
10.1096/FJ.04-2631FJE
P407
P577
2004-10-06T00:00:00Z